Cerity Partners
DNLI icon

Cerity Partners’s Denali Therapeutics DNLI Stock Holding History

Cerity Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
21,587
+8,929
+71% +$183K ﹤0.01% 2361
2026
Q1 		$243K Buy
+12,658
New +$252K ﹤0.01% 2758
2023
Q2 		– Sell
-15,127
Closed -$349K – 1724
2023
Q1 		$349K Buy
+15,127
New +$416K ﹤0.01% 1462

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerity Partners's DNLI Position: Q2 2026 in Review

Cerity Partners increased its Denali Therapeutics (DNLI) stake by 71% in Q2 2026, buying an estimated $183K and bringing the position to 21,587 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #2361.

Cerity Partners first reported a position in DNLI in Q1 2023 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Cerity Partners held 21,587 shares of Denali Therapeutics worth $555K as of Q2 2026.
  • Cerity Partners bought 8,929 Denali Therapeutics shares in Q2 2026, an estimated $183K.
  • Denali Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2361 holding.
  • Cerity Partners first reported a position in Denali Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.